Tag: BetterLife Pharma - Psychedelic Alpha

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

Post published:September 27, 2022
Post category:Press Release

BetterLife and Collaborators to Submit Key Joint Research Publication

Post published:September 7, 2022
Post category:Press Release

Read more about the article BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

Post published:August 25, 2022
Post category:Press Release

Read more about the article BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Post published:July 7, 2022
Post category:Press Release

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

Post published:June 23, 2022
Post category:Press Release

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

Post published:February 15, 2022
Post category:Press Release

Read more about the article BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

Post published:January 20, 2022
Post category:Press Release

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

Post published:January 18, 2022
Post category:Press Release

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

Post published:September 27, 2021
Post category:Press Release

BetterLife Announces Closing of a Non-Brokered Private Placement

Post published:May 14, 2021
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

BetterLife and Collaborators to Submit Key Joint Research Publication

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

BetterLife Announces Closing of a Non-Brokered Private Placement

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.